Professor of Radiation Oncology, University VA School of Medicine
Radiation Oncology
Dr. Tyvin A. Rich, MD
|
|
Give Review
Dr. Tyvin A. Rich is an expert in the field of Radiation Oncology. He went to University of Virginia School of Medicine. He received awards:"Whos Who in Medicine and Healthcare". Doctor Tyvin A. Rich, MD is also published. He has 37 publications published. The lastest publication: "Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
- Anal Carcinoma: Impact of TN Category of Disease on Survival, Disease Relapse, and Colostomy Failure in US Gastrointestinal Intergroup RTOG 98-11 Phase 3 Trial.
- Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.
- RapidArc patient specific mechanical delivery accuracy under extreme mechanical limits using linac log files.
- Impact of Triple-Negative Phenotype on Prognosis of Patients with Breast Cancer Brain Metastases.
- Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Interg...
- Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
- Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy an...
- Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).
- Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphory...
- Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches.
- Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.
- Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Ra...
- US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.
- Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities.
- Multimodality Treatment With Helical Tomotherapy Intensity Modulated Radiotherapy, Capecitabine, and Photodynamic Therapy is Feasible and Well Tolerated in Patients Wi...
- Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
- Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled t...
- Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy.
- Analyzing the symptoms in cancer patients. Disrupted circadian signaling by the epidermal growth factor receptor.
- Preoperative chemoradiotherapy for esophageal cancer: impressive downstaging with acceptable toxicity.
- Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis.
- Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
- In vivo detection of apoptotic cells in the testis using fluorescence labeled annexin V in a mouse model of testicular torsion.
- Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
- Cancer symptom complexes related to alterations in molecular circadian axis signaling.
- Chemoradiotherapy for gastrointestinal cancers.
- Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
- Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
- Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
- Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on ...
- COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
- Postoperative adjuvant therapy for pancreatic cancer.
- Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.
- Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.
- Chronomodulated chemotherapy and irradiation: an idea whose time has come?
Schools
Virginia Commonwealth University School Of Medicine
Georgetown Med DivDc Genl
Massachusetts General Hospital
Mt Vernon HospGray Lab
Procedures Preformed
- Radiation Therapy
Doctors Specialties
- Diagnostic Radiology
- Radiation Oncology
- Radiology
Accepted Insurances
Awards
- Whos Who in Medicine and Healthcare
Education
-
Massachusetts General Hospital -
University of Virginia School of Medicine
Hospital
-
University of Virginia Medical Center
Drug Facts
| NPI NUMBER | 1487785564 | |
| NPPES Provider LastName | RICH | |
| NPPES Provider FirstName | TYVIN | |
| NPPES Provider ZIPCode | 229080001 | |
| NPPES Provider State | VA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 64.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487785564 |
| Last Name Of The Provider | RICH |
| First Name Of The Provider | TYVIN |
| View All |
Similar Doctors
|
Dr. Cynthia A. Spaulding, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Monica Morris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sylvia S. Hendrix, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bruce J. Hillman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Sean J. Martinez, MD |
|
|
Dr. Theodore E. Keats, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick B. Dougherty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tausha Stephens, MD |
|
|
Dr. John L. Duminy, MD |
|
|
Dr. Edwin F. Crandley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kara E. Downs, MD |
|
|
Dr. Kevin P. Orcutt, MD |
|
|
Dr. Bertram W. Maidment III, MD |
|
|
Dr. Jennifer D. Marler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel M. Trifiletti, MD |
|
|
Dr. Kareem Rahbar, MD |
|
|
Dr. Kelli A. Reardon, MD
This Doctor is OpenDoctor Recommended.
|